Activities Report and Appendix 4C for September 2021 Quarter
Melbourne (Australia) – 21 October 2021. Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 September 2021.
Telix today provides its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 September 2021.
Telix CEO Dr. Christian Behrenbruch stated, “Telix has been intensely focused on preparations for the launch of the Company’s first commercial product Illuccix® (TLX591-CDx), while at the same time continuing to effectively advance the programs in its multi-asset core clinical pipeline. The clinical activity underway in 2021 will underpin our transition to a globally-active therapeutic radiopharmaceutical company, and the team continues to work tirelessly towards the goal of bringing additional products to market to unlock the value in our research portfolio.”
To view the full Appendix 4C and Activities Report please click here.
To return to Telix’s homepage please click here.
Telix at ANZSNM Annual Scientific Meeting 2022
9 May 2022 – Corporate Spotlight | Telix supporting and participating in Australian and New Zealand Society of Nuclear Medicine...
First Patient Dosed in Phase II Renal Cancer Theranostics Study
Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 5 May 2022. Telix announces that a first patient has been dosed in...
Telix Further Strengthens European Distribution Network for Illuccix
Melbourne (Australia) and Liège (Belgium)– 22 April 2022. Telix announces agreements with Avanço and THP for the distribution of Telix’s...